![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Granisetron hydrochloride, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2007-051 - Rev 02
This Chemical Type CEP, issued on December 19, 2019, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1695 associated with this CEP further emphasizes